Research Overview: Niclosig
Niclosig 500 mg is an antiprotozoal research compound manufactured by Signature Pharmaceuticals for in-vitro laboratory studies. This compound represents niclosamide, an anthelmintic agent extensively investigated in cellular models for its antiparasitic mechanisms and emerging applications in metabolic research. Scientists at Stroid UK Shop examine niclosamide’s multifaceted biological activities, including its effects on mitochondrial function and cellular energy metabolism pathways.
Laboratory Investigation Properties
Research investigations focus on niclosamide’s mechanism as an uncoupler of oxidative phosphorylation in parasitic organisms. Studies evaluate its interaction with STAT3 signalling pathways and potential modulatory effects on Wnt/β-catenin signalling in cellular models. Niclosamide demonstrates interesting properties in metabolic research, where investigators analyse its effects on AMPK activation and glucose metabolism in cell culture systems. The compound’s ability to interfere with mitochondrial ATP production makes it valuable for studying cellular bioenergetics and metabolic dysfunction models. Researchers investigating miscellaneous research compounds often utilise niclosamide alongside other metabolic modulators to examine complex cellular pathways and drug interaction studies.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Compound | Niclosamide |
| Dosage Strength | 500 mg per tablet |
| Manufacturer | Signature Pharmaceuticals Ltd. |
| CAS Number | 50-65-7 |
| Molecular Formula | C₁₃H₈Cl₂N₂O₄ |
| Molecular Weight | 327.12 g/mol |
| Storage Requirements | Room temperature, dry environment |
| Research Applications | Antiprotozoal studies, metabolic research |
Laboratory studies compare niclosamide’s efficacy against various protozoal species in controlled experimental conditions. Researchers studying selective androgen receptor modulators and research peptides often incorporate metabolic modulators like niclosamide to investigate potential synergistic effects on cellular metabolism and energy homeostasis pathways.
Research Compliance Statement
Niclosig 500 mg is supplied exclusively for in-vitro research purposes and laboratory investigations. This compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure proper laboratory protocols and safety measures when handling this material. All studies should be conducted under appropriate institutional oversight with proper documentation of experimental procedures and results.
